[1]康冠楠,党 萍,马清艳,等.芪参益肺汤联合康复新液治疗老年肺结核疗效及对患者肺功能、免疫功能的影响[J].陕西中医,2021,(10):1393-1396.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.017]
　KANG Guannan,DANG Ping,MA Qingyan,et al.Effect of Qishen Yifei decoction combined with Kangfuxin solution in the treatment of senile pulmonary tuberculosis and its effect on lung function and immune function[J].,2021,(10):1393-1396.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.017]
点击复制

芪参益肺汤联合康复新液治疗老年肺结核疗效及对患者肺功能、免疫功能的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年10期
页码:
1393-1396
栏目:
临床研究
出版日期:
2021-10-05

文章信息/Info

Title:
Effect of Qishen Yifei decoction combined with Kangfuxin solution in the treatment of senile pulmonary tuberculosis and its effect on lung function and immune function
作者:
康冠楠; 党 萍; 马清艳; 刘晓飞; 耿书军; 宋 韬; 侯莉莉
(河北省胸科医院结核四科,河北 石家庄 050041)
Author(s):
KANG Guannan; DANG Ping; MA Qingyan; LIU Xiaofei; GENG Shujun; SONG Tao; HOU Lili
(Department of Tuberculosis Fourth,Hebei Chest Hospital,Shijiazhuang 050041,China)
关键词:
老年肺结核;  芪参益肺汤;  康复新液;  肺功能;  细胞免疫;  体液免疫
Keywords:
Senile tuberculosis;  Qishen Yifei decoction;  Kangfuxin solution;  Lung function;  Cellular immunity;  Humoral immunity
分类号:
R 521
DOI:
DOI:10.3969/j.issn.1000-7369.2020.10.017
文献标志码:
A
摘要:
目的:探讨中药芪参益肺汤联合康复新液治疗老年肺结核的临床疗效。方法:选择老年肺结核患者86例,按照随机数字表法分为两组,每组43例,两组均规范化疗,对照组在化疗基础上应用康复新液,治疗组在化疗基础上应用中药芪参益肺汤联合康复新液。比较两组治疗15 d、1个月、2个月时痰菌转阴率和病灶吸收情况,并比较两组治疗前后1 s用力呼吸量/用力肺活量(FEV1/FVC)比值,用力呼气峰值流速(PEF)和肺活量(FVC),并比较T淋巴细胞亚群CD3+、CD4+、CD8+含量和CD4+/CD8+比值,比较血清免疫球蛋白(Ig)A、IgG和IgM水平。结果:治疗1个月、2个月时治疗组转阴率高于对照组(P<0.05),病灶吸收情况优于对照组,差异均有统计学意义(P<0.05); 治疗后治疗组FEV1/FVC、PEF、FVC均高于对照组,CD3+、CD4+、CD4+/CD8+值均高于对照组,CD8+低于对照组,血清IgA、IgG、IgM水平均高于对照组,差异均有统计学意义(P<0.05)。结论:芪参益肺汤联合康复新液可增强机体免疫力,从而提高痰菌转阴率,促进结核病灶吸收,改善肺功能,治疗老年肺结核效果显著。
Abstract:
Objective:To investigate the clinical efficacy of Qishen Yifei decoction combined with Kangfuxin solution in the treatment of senile pulmonary tuberculosis.Methods:86 elderly tuberculosis patients were selected and divided into two groups according to the random number table method,with 43 cases in each group.Both groups received chemotherapy.The control group was treated with Kangfuxin solution on the basis of chemotherapy,and the treatment group was treated with Qishen Yifei decoction combined with Kangfuxin solution on the basis of chemotherapy.Compare two groups of treatment for 15 d,1 month,2 months of sputum bacterium negative conversion rate and state of lesions absorption,and compare the two groups ratio of forced expiratory volume in 1 second/forced vital capacity(FEV1/FVC),peak expiratory flow(PEF)and forced vital capacity before and after treatment,and compare the T lymphocyte subsets CD3+,CD4+,CD8+ and CD4+/CD8+ ratio,compare serum immunoglobulin(Ig)A,IgG and IgM levels.Results:After 1 month and 2 months of treatment,the rate of negative transformation in the treatment group was higher than that in the control group(P<0.05),and the absorption of lesions was better than that in the control group(P<0.05).The differences were statistically significant.After treatment,FEV1/FVC,PEF and FVC in the treatment group were all higher than those in the control group,values of CD3+,CD4+ and CD4+/CD8+ were higher than those in the control group,and CD8+ was lower than that in the control group.Serum IgA,IgG and IgM levels were all higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:The combination of Qishen Yifei decoction and Kangfuxin solution can enhance the immunity of the body,so as to improve the negative transformation rate of sputum bacteria,promote the absorption of tuberculosis lesions,improve lung function,and have a significant effect on the treatment of senile tuberculosis.

参考文献/References:

[1] 王彦富,綦 峥,张铁林,等.黑龙江省2017—2018年老年活动性肺结核流行病学特征分析[J].中国公共卫生管理,2020,36(2):234-238.
[2] 赖 铿,吴桂锋,雷 宇,等.2014—2018年广州市肺结核发病空间分布特征分析[J].中国防痨杂志,2020,42(4):327-334.
[3] 吴 妍,李 琦.老年肺结核的诊治现状与进展[J].中国防痨杂志,2015,37(9):975-978.
[4] 杨元利,张永峰,窦权利.老年肺结核病130例临床分析[J].陕西医学杂志,2019,48(12):1691-1693.
[5] 杨晓明,刘忠达,张尊敬,等.老年肺结核临床特点及中医药治疗概况[J].结核病与肺部健康杂志,2018,7(3):213-216.
[6] 张少言,鹿振辉,马子风,等.中医药治疗肺结核的新进展[J].中医药导报,2017,23(11):79-81,85.
[7] 高 娴,李洪智,杨 洁.滋阴润肺抗痨方中药雾化治疗对耐多药肺结核病理状态改善效应及对患者细胞免疫功能的影响[J].陕西中医,2020,41(2):187-190.
[8] 何怀阳,张小萍.益气健脾法治疗老年肺结核探讨[J].辽宁中医杂志,2006,33(4):409-410.
[9] 王 姬,谢固雅,冯马龙.康复新液联合标准化疗方案治疗空洞型肺结核并发咯血93例[J].医药导报,2018,37(4):429-433.
[10] 中华医学会.临床诊疗指南?结核病分册[M].北京:人民卫生出版社,2005:122-123.
[11] 中华人民共和国卫生部.中药新药临床研究指导原则[M].北京:中国医药科技出版社, 2002:54-56.
[12] 彭明丽,陈 明,温筱煦,等.肺结核患者利福喷丁血药浓度监测研究[J].中国药物应用与监测,2018,15(2):81-84.
[13] 陶 磊,赵志忍,张乐天.利福平胶囊(Ⅱ)治疗肺结核的临床效果及对患者肝功能的影响[J].中国医药,2020,15(5):681-684.
[14] 戴 磊,黎伟林,黎志刚,等.基于证素辨证的佛山市高明区肺结核病中医证候分布特征[J].中医药临床杂志,2021,33(6):1151-1153.
[15] 官 武.肺痨康汤联合抗结核药物对老年肺结核患者免疫功能及炎症因子水平的影响[J].药品评价,2020,17(12):10-12.
[16] 王 姬,谢固雅,冯马龙.康复新液联合标准化疗方案治疗空洞型肺结核并发咯血93例[J].医药导报,2018,37(4):429-433.
[17] 木台力甫?莫拉吾提,刘 鹏,周 勇,等.胸腺五肽辅助治疗老年结核病的疗效评估[J].中国医刊,2019,54(6):679-681.
[18] 胡清利,孙强中.免疫增强剂联合化疗治疗矽肺合并肺结核对免疫及肺功能的影响[J].临床肺科杂志,2018,23(3):399-401,405.
[19] 包小玲,刘振专,陈述文,等.浅析细胞免疫与体液免疫功能检测在重症结核病患者检测中的临床价值[J].中华临床医师杂志:电子版,2016,21(1):46-48.
[20] 李 君.胸腺肽α1辅助抗生素持续治疗对结核病患者肺功能及免疫功能的影响[J].河北医药,2020,42(6):875-878.

备注/Memo

备注/Memo:
基金项目:河北省医学科学研究课题(20191033)
更新日期/Last Update: 2021-10-09